Biotime Newswire

Biotime Newswire

Comprehensive Real-Time News Feed for Biotime.

Results 1 - 20 of 118 in Biotime

  1. BioTime, Inc. (BTX) Short Interest Up 3.7% in MayRead the original story w/Photo

    Tuesday Jun 12 | IntersportsWire

    BioTime, Inc. was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 9,427,853 shares, a growth of 3.7% from the May 15th total of 9,095,764 shares. Based on an average daily volume of 267,081 shares, the days-to-cover ratio is presently 35.3 days.

    Comment?

  2. BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX SharesRead the original story w/Photo

    Friday Jun 8 | The Galveston County Daily News

    Jun 8, 2018--BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, announced that a draft registration statement on Form 10 was submitted to the U.S. Securities and Exchange Commission . The draft registration statement relates to the proposed distribution of some or all of BioTime's shares of AgeX Therapeutics, Inc. common stock, on a pro rata basis, to BioTime's shareholders of record as of a date to be determined.

    Comment?

  3. BioTime (BTX) Lifted to "Hold" at Zacks Investment ResearchRead the original story w/Photo

    Saturday Jun 2 | IntersportsWire

    According to Zacks, "BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body.

    Comment?

  4. Equities Research Analysts' Updated EPS Estimates for May, 30th...Read the original story w/Photo

    Wednesday May 30 | AmericanBankingNews.com

    ... " was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, "BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of ...

    Comment?

  5. BioTime Announces $1.9 Million Grant for Continued Development of OpRegen for Dry-AMDRead the original story w/Photo

    Tuesday May 29 | The Galveston County Daily News

    May 29, 2018--BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels from the Israel Innovation Authority . The grant provides funding for the continued development of OpRegen A , and to date the IIA has provided annual grants totaling over $13 million.

    Comment?

  6. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Tuesday May 29 | Business Wire

    ... the European Medicines Agency (EMA) has completed formal validation of Acorda's Marketing Authorization... Resumen: BioTime anuncia subvencin de 1,9 millones de dlares para el desarrollo continuado de OpRegen para la degeneracin macular asociada con ...

    Comment?

  7. BioTime granted $1.9M for continued development of OpRegen for dry-AMDRead the original story w/Photo

    Tuesday May 29 | Seeking Alpha

    BioTime has been awarded a new grant for 2018 of up to NIS6.9M from the Israel Innovation Authority for the continued development of OpRegen.

    Comment?

  8. Dimensional Fund Advisors LP Increased Johnson & Johnson (JNJ)...Read the original story w/Photo

    Sunday May 27 | Hill Country Times

    ... while stock markets declined. The hedge fund held 297,855 shares of the technology company at the end of 2017Q4, [] Biotime (BTX) Shareholder Broadwood Capital Lifted Its Stake; As Citrix Systems (CTXS) Valuation Rose, Holder Renaissance Group ...

    Comment?

  9. BioTime (BTX) Short Interest Up 3.3% in MayRead the original story w/Photo

    Thursday May 24 | IntersportsWire

    BioTime was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 9,095,764 shares, an increase of 3.3% from the April 30th total of 8,805,300 shares. Currently, 7.3% of the shares of the company are short sold.

    Comment?

  10. Biotime (BTX) Shareholder Broadwood Capital Lifted Its Stake; As...Read the original story w/Photo

    Wednesday May 23 | Hill Country Times

    Biotime Shareholder Broadwood Capital Lifted Its Stake; As Citrix Systems Valuation Rose, Holder Renaissance Group Trimmed Its Holding Neal C. Bradsher increased its stake in Biotime Inc by 9.87% based on its latest 2017Q4 regulatory filing with the SEC. Broadwood Capital Inc bought 2.69 million shares as the company's stock rose 5.22% while stock markets declined.

    Comment?

  11. BioTime (BTX) Given Consensus Recommendation of "Hold" by BrokeragesRead the original story w/Photo

    May 13, 2018 | AmericanBankingNews.com

    BioTime has been given an average recommendation of "Hold" by the six analysts that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation and two have issued a buy recommendation on the company.

    Comment?

  12. Biotime (BTX) Market Valuation Rose While Broadwood Capital Has...Read the original story w/Photo

    May 13, 2018 | Hill Country Times

    Biotime Market Valuation Rose While Broadwood Capital Has Increased Position by $5.38 Million; As Qualcomm Com Stock Price Declined, Holder Liberty Capital Management Cut Its Holding Neal C. Bradsher increased its stake in Biotime Inc by 9.87% based on its latest 2017Q4 regulatory filing with the SEC. Broadwood Capital Inc bought 2.69 million shares as the company's stock rose 5.22% while stock markets declined.

    Comment?

  13. 's Daily Biotech Pulse: FDA Panel Nod For Akcea,...Read the original story w/Photo

    May 11, 2018 | Benzinga

    ... The company increased its gross margin guidance for FY18 and reaffirmed its biopreservation media revenue forecast. BioTime, Inc. (NYSE: BTX ) reported a Q1 loss of 50 cents per share, wider than the 7 cents loss expected by analysts. Revenues of ...

    Comment?

  14. Short Interest in BioTime, Inc. (BTX) Increases By 2.8%Read the original story w/Photo

    May 9, 2018 | AmericanBankingNews.com

    BioTime, Inc. was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 8,805,300 shares, a growth of 2.8% from the April 13th total of 8,562,159 shares.

    Comment?

  15. BioTime (BTX) Set to Announce Earnings on TuesdayRead the original story w/Photo

    May 7, 2018 | Daily Political

    BioTime is scheduled to be announcing its earnings results after the market closes on Tuesday, May 8th. Analysts expect the company to announce earnings of per share for the quarter.

    Comment?

  16. BioTime (BTX) Scheduled to Post Quarterly Earnings on TuesdayRead the original story w/Photo

    May 1, 2018 | AmericanBankingNews.com

    BioTime will be issuing its quarterly earnings data after the market closes on Tuesday, May 8th. Analysts expect the company to announce earnings of per share for the quarter.

    Comment?

  17. BioTime, Inc. (BTX) Holdings Increased by Two Sigma Advisers LPRead the original story w/Photo

    Apr 27, 2018 | IntersportsWire

    Two Sigma Advisers LP grew its holdings in shares of BioTime, Inc. by 422.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 90,053 shares of the biotechnology company's stock after acquiring an additional 72,803 shares during the quarter.

    Comment?

  18. Renaissance Technologies LLC Purchases 807,500 Shares of BioTime, Inc.Read the original story w/Photo

    Apr 26, 2018 | AmericanBankingNews.com

    Renaissance Technologies LLC lifted its position in BioTime, Inc. by 206.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The institutional investor owned 1,197,800 shares of the biotechnology company's stock after acquiring an additional 807,500 shares during the quarter.

    Comment?

  19. Short Interest in BioTime, Inc. (BTX) Grows By 3.7%Read the original story w/Photo

    Apr 24, 2018 | AmericanBankingNews.com

    BioTime, Inc. was the target of a significant growth in short interest during the month of April. As of April 13th, there was short interest totalling 8,562,159 shares, a growth of 3.7% from the March 30th total of 8,258,973 shares.

    Comment?

  20. Analysts Set BioTime, Inc. (BTX) Price Target at $7.25Read the original story w/Photo

    Apr 23, 2018 | Daily Political

    Shares of BioTime, Inc. have earned an average rating of "Hold" from the six brokerages that are covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation and two have given a buy recommendation to the company.

    Comment?